Scholarlink

<p>This pilot study evaluated the diagnostic performance of a triple-tracer PET/CT protocol in 13 patients with advanced, high-grade neuroendocrine neoplasms (NENs; Ki-67 &gt; 40%). NENs are characterized by biological heterogeneity and variable tracer avidity, complicating accurate staging and therapy selection. Each patient underwent imaging with [18F] FDG (metabolic activity), [68Ga] Ga-DOTANOC (somatostatin receptor expression), and [68Ga] Ga-FAPI-04 (fibroblast activation) within one week, enabling complementary biological assessment. A total of 92 metastatic lesions were analyzed (29 hepatic, 36 osseous, 27 nodal). In the liver, [18F] FDG demonstrated the highest uptake (SUV<sub>max</sub> 18.6 ± 5.3) compared with [68Ga] Ga- FAPI (12.3 ± 3.5) and [68Ga] Ga-DOTANOC (7.8 ± 2.6). Bone metastases were predominantly [68Ga] Ga-FAPI-avid (SUV<sub>max</sub> 9.1 ± 3.0), with 23% detected by [68Ga] Ga-FAPI. Lymph nodes exhibited mixed avidity ([18F] FDG 10.2 ± 4.3; [68Ga] Ga- FAPI 7.0 ± 2.7; [68Ga] Ga-DOTANOC 5.2 ± 3.0). Marked inter- and intra-patient heterogeneity was observed across tracers. The combined protocol improved lesion characterization, reduced false negatives, and revealed heterogeneity that would have been underestimated by single-tracer imaging. These findings demonstrate the feasibility and potential clinical utility of integrating [18F] FDG, [68Ga] Ga-DOTANOC and [68Ga] Ga-FAPI PET in high-grade NENs, providing a more comprehensive theranostics roadmap. Given the limited sample size and statistical power, larger prospective studies are warranted to validate these preliminary observations and refine patient selection for multitracer imaging or future “cocktail” therapy strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Triple-tracer PET (18F-FDG, 68Ga-DOTANOC, 68Ga-FAPI) maps inter- and intra-lesional heterogeneity in metastatic high-grade neuroendocrine neoplasms

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月11日

查看全文
  • Prathap Jayachandra Hosahalli,
  • S. P. Somashekar,
  • D. N. Bhoomika,
  • B. R. Abhijit,
  • Vishwanath Joshi,
  • Prashanth Ramachandra Guthlu,
  • Rajkumar Krishnappa,
  • Mita Kumarswamy Kallur,
  • Palak Wadhwa,
  • K. R. Ashwin,
  • C. Rohit Kumar,
  • Sai Vivek,
  • Suva Lakshmi,
  • Prajwal Rajaghatta Kumaraswamy,
  • B. Shameer Ahmed

摘要

This pilot study evaluated the diagnostic performance of a triple-tracer PET/CT protocol in 13 patients with advanced, high-grade neuroendocrine neoplasms (NENs; Ki-67 > 40%). NENs are characterized by biological heterogeneity and variable tracer avidity, complicating accurate staging and therapy selection. Each patient underwent imaging with [18F] FDG (metabolic activity), [68Ga] Ga-DOTANOC (somatostatin receptor expression), and [68Ga] Ga-FAPI-04 (fibroblast activation) within one week, enabling complementary biological assessment. A total of 92 metastatic lesions were analyzed (29 hepatic, 36 osseous, 27 nodal). In the liver, [18F] FDG demonstrated the highest uptake (SUVmax 18.6 ± 5.3) compared with [68Ga] Ga- FAPI (12.3 ± 3.5) and [68Ga] Ga-DOTANOC (7.8 ± 2.6). Bone metastases were predominantly [68Ga] Ga-FAPI-avid (SUVmax 9.1 ± 3.0), with 23% detected by [68Ga] Ga-FAPI. Lymph nodes exhibited mixed avidity ([18F] FDG 10.2 ± 4.3; [68Ga] Ga- FAPI 7.0 ± 2.7; [68Ga] Ga-DOTANOC 5.2 ± 3.0). Marked inter- and intra-patient heterogeneity was observed across tracers. The combined protocol improved lesion characterization, reduced false negatives, and revealed heterogeneity that would have been underestimated by single-tracer imaging. These findings demonstrate the feasibility and potential clinical utility of integrating [18F] FDG, [68Ga] Ga-DOTANOC and [68Ga] Ga-FAPI PET in high-grade NENs, providing a more comprehensive theranostics roadmap. Given the limited sample size and statistical power, larger prospective studies are warranted to validate these preliminary observations and refine patient selection for multitracer imaging or future “cocktail” therapy strategies.